ARGX-119 is a humanized agonistic monoclonal antibody targeting Muscle-Specific Kinase (MuSK), intended for research use. It is applied in preclinical studies of neuromuscular disorders, such as myasthenia gravis, for both in vitro mechanistic investigations and in vivo model validation.